> top > docs > PubMed:17897478 > annotations

PubMed:17897478 JSONTXT

Annnotations TAB JSON ListView MergeView

Inflammaging

Id Subject Object Predicate Lexical cue
T1 0-176 Sentence denotes Salmeterol plus fluticasone propionate versus fluticasone propionate plus montelukast: a randomised controlled trial investigating the effects on airway inflammation in asthma.
T2 177-188 Sentence denotes BACKGROUND:
T3 189-400 Sentence denotes Few studies have compared treatment strategies in patients with asthma poorly controlled on low dose inhaled corticosteroids, and little is known about the effects of different treatments on airway inflammation.
T4 401-686 Sentence denotes In this double-blind, placebo-controlled, parallel group study, we compared the effects of salmeterol plus fluticasone propionate (FP) (Seretide; SFC) and FP plus montelukast (FP/M) on sputum inflammatory markers, airway responsiveness, lung function, and symptoms in adult asthmatics.
T5 687-695 Sentence denotes METHODS:
T6 696-759 Sentence denotes Sixty-six subjects were randomised to SFC or FP/M for 12 weeks.
T7 760-888 Sentence denotes The primary outcome was changes in neutrophil, eosinophil, macrophage, lymphocyte, and epithelial cell levels in induced sputum.
T8 889-1035 Sentence denotes Additional outcomes included the change in other sputum markers of airway inflammation, airway responsiveness, symptom control, and lung function.
T9 1036-1044 Sentence denotes RESULTS:
T10 1045-1190 Sentence denotes Both treatments had no significant effect on induced sputum inflammatory cells, although there was a trend for a reduction in sputum eosinophils.
T11 1191-1350 Sentence denotes Both treatments significantly improved airway responsiveness, whereas SFC generally led to greater improvements in symptom control and lung function than FP/M.
T12 1351-1480 Sentence denotes FP/M led to significantly greater reductions in sputum cysteinyl leukotrienes than SFC (treatment ratio 1.80; 95% CI 1.09, 2.94).
T13 1481-1492 Sentence denotes CONCLUSION:
T14 1493-1623 Sentence denotes Both treatments led to similar control of eosinophilic airway inflammation, although PEF and symptom control were better with SFC.
T15 1624-1655 Sentence denotes STUDY NUMBER: SAM40030 (SOLTA).
T1 0-176 Sentence denotes Salmeterol plus fluticasone propionate versus fluticasone propionate plus montelukast: a randomised controlled trial investigating the effects on airway inflammation in asthma.
T2 177-188 Sentence denotes BACKGROUND:
T3 189-400 Sentence denotes Few studies have compared treatment strategies in patients with asthma poorly controlled on low dose inhaled corticosteroids, and little is known about the effects of different treatments on airway inflammation.
T4 401-686 Sentence denotes In this double-blind, placebo-controlled, parallel group study, we compared the effects of salmeterol plus fluticasone propionate (FP) (Seretide; SFC) and FP plus montelukast (FP/M) on sputum inflammatory markers, airway responsiveness, lung function, and symptoms in adult asthmatics.
T5 687-695 Sentence denotes METHODS:
T6 696-759 Sentence denotes Sixty-six subjects were randomised to SFC or FP/M for 12 weeks.
T7 760-888 Sentence denotes The primary outcome was changes in neutrophil, eosinophil, macrophage, lymphocyte, and epithelial cell levels in induced sputum.
T8 889-1035 Sentence denotes Additional outcomes included the change in other sputum markers of airway inflammation, airway responsiveness, symptom control, and lung function.
T9 1036-1044 Sentence denotes RESULTS:
T10 1045-1190 Sentence denotes Both treatments had no significant effect on induced sputum inflammatory cells, although there was a trend for a reduction in sputum eosinophils.
T11 1191-1350 Sentence denotes Both treatments significantly improved airway responsiveness, whereas SFC generally led to greater improvements in symptom control and lung function than FP/M.
T12 1351-1480 Sentence denotes FP/M led to significantly greater reductions in sputum cysteinyl leukotrienes than SFC (treatment ratio 1.80; 95% CI 1.09, 2.94).
T13 1481-1492 Sentence denotes CONCLUSION:
T14 1493-1623 Sentence denotes Both treatments led to similar control of eosinophilic airway inflammation, although PEF and symptom control were better with SFC.
T15 1624-1655 Sentence denotes STUDY NUMBER: SAM40030 (SOLTA).

PubMed_Structured_Abstracts

Id Subject Object Predicate Lexical cue
T1 189-686 BACKGROUND denotes Few studies have compared treatment strategies in patients with asthma poorly controlled on low dose inhaled corticosteroids, and little is known about the effects of different treatments on airway inflammation. In this double-blind, placebo-controlled, parallel group study, we compared the effects of salmeterol plus fluticasone propionate (FP) (Seretide; SFC) and FP plus montelukast (FP/M) on sputum inflammatory markers, airway responsiveness, lung function, and symptoms in adult asthmatics.
T2 696-1035 METHODS denotes Sixty-six subjects were randomised to SFC or FP/M for 12 weeks. The primary outcome was changes in neutrophil, eosinophil, macrophage, lymphocyte, and epithelial cell levels in induced sputum. Additional outcomes included the change in other sputum markers of airway inflammation, airway responsiveness, symptom control, and lung function.
T3 1045-1480 RESULTS denotes Both treatments had no significant effect on induced sputum inflammatory cells, although there was a trend for a reduction in sputum eosinophils. Both treatments significantly improved airway responsiveness, whereas SFC generally led to greater improvements in symptom control and lung function than FP/M. FP/M led to significantly greater reductions in sputum cysteinyl leukotrienes than SFC (treatment ratio 1.80; 95% CI 1.09, 2.94).
T4 1493-1655 CONCLUSIONS denotes Both treatments led to similar control of eosinophilic airway inflammation, although PEF and symptom control were better with SFC. STUDY NUMBER: SAM40030 (SOLTA).

PMID_GLOBAL

Id Subject Object Predicate Lexical cue mondo_id
T1 169-175 DiseaseOrPhenotypicFeature denotes asthma 0004979
T2 253-259 DiseaseOrPhenotypicFeature denotes asthma 0004979
T3 638-642 DiseaseOrPhenotypicFeature denotes lung 0021117
T4 1021-1025 DiseaseOrPhenotypicFeature denotes lung 0021117
T5 1326-1330 DiseaseOrPhenotypicFeature denotes lung 0021117

PubmedHPO

Id Subject Object Predicate Lexical cue
T1 253-259 HP_0002099 denotes asthma
T2 416-421 HP_0000618 denotes blind